Cyclo Therapeutics Inc

NASDAQ:CYTHUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).

Contact Information

Headquarters

6714 Nw 16Th Street, Suite BGAINESVILLE, FL, United States 32653

Phone

386-418-8060

Fax

---

Executives

Independent Chairman of the Board

Markus Sieger

Chief Executive Officer, Director

N. Scott Fine

Independent Vice Chairman of the Board

F. Patrick Ostronic

Founder, Independent Director

C.E. Strattan

Chief Financial Officer, Secretary

Joshua Fine